| ASDAS CRP < 1.3 (n = 31) | ASDAS CRP ≥ 1.3 (n = 49) | P |
---|---|---|---|
Male gender | 27/31 (87.1%) | 39/49 (79.6%) | 0.548 |
HLA-B27 positivity | 20/27 (74.1%) | 37/42 (88.1%) | 0.193 |
Smoking | 4/25 (16.0%) | 19/41 (46.3%) | 0.016* |
Baseline: | |||
 Age, years | 32.3 ± 9.9 | 39.8 ± 11.8 | 0.004* |
 Duration of disease, years | 10.6 ± 9.3 | 14.7 ± 9.8 | 0.047* |
Co-medication: | |||
 NSAID | 23/31 (74.2%) | 35/49 (71.4%) | 1.000 |
 DMARD | 27/31 (87.1%) | 37/49 (75.5%) | 0.259 |
 MTX | 11/31 (35.5%) | 21/49 (42.9%) | 0.640 |
 SSZ | 22/31 (70.9%) | 22/49 (44.9%) | 0.037* |
 BASDAI | 4.6 ± 2.2 | 5.8 ± 2.0 | 0.027* |
 BASFI | 4.4 ± 2.0 | 6.2 ± 2.5 | 0.003* |
 BASMI | 3.6 ± 2.8 | 5.0 ± 2.7 | 0.034* |
 ASQol | 10.6 ± 5.6 | 11.2 ± 4.8 | 0.669 |
 ASDAS – CRP | 3.5 ± 0.9 | 3.9 ± 1.0 | 0.126 |
 CRP (mg/L) | 20.3 (9.7, 36.7) | 24.6 (14.9, 38.9) | 0.664 |
 ESR (mm/h) | 23.0 (10.3, 32.0) | 21.0 (12.5, 36.5) | 0.650 |
 1st anti-TNF retention | 22/31 (71.0%) | 23/49 (46.9%) | 0.040* |
 Last anti-TNF treatment, weeks | 176.9 ± 85.2 | 182.1 ± 106.2 | 0.820 |